loading page

Long-term outcome of Tyrosine Kinase Inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase: A single-center experience in China
  • +3
  • yongzhi zheng,
  • Cai Chen,
  • Hao Zheng,
  • Danhui Fu,
  • Jian Li,
  • Jianda Hu
yongzhi zheng
Fujian Medical University Union Hospital

Corresponding Author:[email protected]

Author Profile
Cai Chen
Fujian Medical University Union Hospital
Author Profile
Hao Zheng
Fujian Medical University Union Hospital
Author Profile
Danhui Fu
Fujian Medical University Union Hospital
Author Profile
Jian Li
Fujian Medical University Union Hospital
Author Profile
Jianda Hu
Fujian Medical University Union Hospital
Author Profile

Abstract

Backgroud: Tyrosine kinase inhibitors (TKIs) has gradually replaced HSCT as the first-line treatment for pediatric patients with chronic-phase Chronic myeloid leukemia (CML-CP). However, there are few reports detailing the long-term effect and safety of TKIs in Chinese children with CML-CP. Procedure: A total of 58 patients (43 children and 15 adolescents) with newly diagnosed CML-CP received imatinib mesylate (IM) as first-line therapy and 2G-TKIs as second-line therapy. The responses and safety to TKI therapy, and the rates of overall survival (OS), progression-free survival (PFS) and event-free survival (EFS) were assessed. Results: After 3 months of IM treatment, 91.4% (53/58) of patients achieved complete hematologic response (CHR). Fifty-one patients received further IM treatment for up to 12 months, and 88.2% (45/51) of them achieved major cytogenetic response (MCyR), with 68.6% (35/51) achieving complete cytogenetic response (CCyR). The cumulative incidence of achieving major molecular response (MMR) was 45.1% (23/51) and 66.0% (31/47) after 12 months and 18 months from initial IM treatment, respectively. Sixteen patients were switched to second-generation TKIs (2G-TKIs), dasatinib (n=8) and nilobinib (n=8), due to lack of response to IM treatment. Among them, 11 patients (68.8%) achieved MMR at a median time of 3.7 months. With a median follow-up duration of 44.8 months, the 9-year overall survival rate (OS) was 81.1%, the 9-year progression-free survival rate (PFS) was 80.5%, and the 9-year event-free survival rate (EFS) was 44.4%. Conclusion: IM as first-line therapy and 2G-TKI as second-line therapy are effective long-term therapeutic measures for children and adolescents in CML-CP.